Ischemia-modified albumin in acute aortic dissection.

Area of Science:

• Cardiology
• Biomarkers
• Aortic Diseases

Background:

• Acute aortic dissection (AOD) is a life-threatening condition requiring prompt diagnosis and treatment.
• Ischemia-modified albumin (IMA) is a potential biomarker for myocardial ischemia, distinct from cardiac enzymes released during necrosis.

Purpose of the Study:

• To investigate for the first time whether IMA levels are elevated in patients with AOD at presentation or following surgical repair.
• To assess the potential of IMA as a diagnostic marker in AOD.

Main Methods:

• A study involving 46 consecutive patients with documented AOD, 13 patients with ascending aortic aneurysms, and 46 healthy controls.
• Measurement of IMA, cardiac enzymes, N-terminal pro-B-type natriuretic peptide, albumin, C-reactive protein (CRP), and D-dimers at multiple time points: admission, 24 hours post-operatively, and 4 days post-operatively.
• Blood samples were collected within 23±17 hours of symptom onset.

Main Results:

• IMA levels did not significantly differ between AOD patients, chronic aneurysm patients, and controls at presentation.
• IMA levels remained unchanged after surgical repair of the aorta.
• Baseline IMA showed a positive correlation with the time from symptom onset and C-reactive protein (CRP) levels.

Conclusions:

• Ischemia-modified albumin (IMA) is not elevated in acute aortic dissection (AOD) when assessed within approximately 23 hours of symptom onset.
• IMA levels do not increase following aortic dissection surgery.
• IMA is not a reliable biomarker for the early diagnosis or post-operative monitoring of AOD.